The Gut Health Gender Gap: Why Research Still Focuses on Male Bodies

The Invisible Epidemic

Irritable bowel syndrome affects an estimated 10 to 15 percent of the global population. In most countries studied, women are diagnosed at roughly twice the rate of men. Autoimmune conditions — many of which involve gastrointestinal symptoms — affect approximately 78 percent of women. Inflammatory bowel disease, celiac disease, and functional dyspepsia all show significant gender disparities in prevalence.

And yet, the vast majority of gut health research has been conducted on male subjects, using male animals, and male cell lines. The result is a medical establishment that does not fully understand how women's digestive systems work, how diseases manifest differently in women, or how treatments should be tailored to account for sex-based differences.

We have built an entire field of medicine on the assumption that the male body is the default. Women's guts — and the conditions that affect them — have been an afterthought.

The Research Bias

The gender bias in medical research is well documented, but it is particularly acute in gastroenterology. A 2020 analysis published in *Gastroenterology* found that clinical trials in inflammatory bowel disease enrolled approximately 45 percent women, despite women making up the majority of patients. Functional gastrointestinal disorders, which disproportionately affect women, were even more underrepresented.

The bias extends to basic science. Animal studies — the foundation of preclinical research — have historically used male animals exclusively. The rationale was that the oestrogen cycle introduced variability that complicated results. The consequence is that we know remarkably little about how gut function, gut microbiome composition, and gut immune responses differ between sexes.

In India, where gastrointestinal conditions are among the most common reasons for medical consultation, the research gap is particularly consequential. Indian populations have distinct dietary patterns, microbiome profiles, and disease patterns that are not well captured by Western research. The combination of a gender bias and a geographical bias means that Indian women with gut conditions are doubly underserved by the evidence base.

When research studies exclude women and when the research that exists is conducted on Western populations, Indian women are studying a disease that was never mapped for them.

The Microbiome and Sex

The gut microbiome — the community of trillions of bacteria that live in the digestive tract — is increasingly recognised as central to health, influencing everything from immune function to mental health. And there are significant sex-based differences in microbiome composition.

Research published in *Nature Reviews Gastroenterology & Hepatology* has documented that women and men have different microbiome profiles, with women generally showing greater microbial diversity. These differences are influenced by sex hormones — oestrogen and progesterone modulate gut bacteria populations — and they change across the menstrual cycle, during pregnancy, and after menopause.

These differences have clinical implications. The way a woman's gut processes food, responds to infection, and develops disease is not identical to a man's. A treatment that works for a man may be less effective for a woman — not because women are less responsive but because the mechanism of the condition differs.

In India, where dietary patterns — high carbohydrate, high spice, varied fermentation practices — create distinct microbiome environments, the sex-gender-microbiome interaction is likely even more complex. But almost no research has been conducted on this intersection in Indian populations.

The microbiome is not gender-neutral. It is shaped by hormones, by diet, by culture, and by sex. Ignoring these differences is ignoring the biology itself.

IBS and the Dismissal of Women's Pain

Irritable bowel syndrome is one of the most common conditions in gastroenterology clinics worldwide. It is also one of the most dismissed. Because IBS has no visible pathology — no tumour, no inflammation, no structural abnormality — it has historically been dismissed as a functional disorder, a fancy term for "nothing is wrong."

Women with IBS are disproportionately affected by this dismissal. They are more likely than men to be diagnosed with IBS rather than a more serious condition, and they are more likely to be told their symptoms are stress-related. The implication is that their pain is psychological, not physical.

In India, where gastrointestinal complaints are common and often attributed to diet, stress, or "digestive weakness," women with IBS face a particularly difficult diagnostic landscape. The condition is often managed with over-the-counter remedies and dietary advice rather than being taken seriously as a chronic illness that requires comprehensive treatment.

Telling a woman with IBS that her pain is stress-related is not a diagnosis. It is a dismissal.

Autoimmune Disease and the Gut

Autoimmune conditions — in which the immune system attacks the body's own tissues — are significantly more common in women than in men. Many autoimmune conditions involve the gastrointestinal tract: celiac disease, inflammatory bowel disease, autoimmune gastritis. The gender disparity is stark: approximately 80 percent of autoimmune disease patients are women.

The reasons for this disparity are not fully understood but are believed to involve the interaction of sex hormones, X chromosome genetics, and immune system regulation. Oestrogen, which is present at higher levels in women, modulates immune function in ways that may increase the risk of autoimmune response.

In India, autoimmune disease is an increasing burden. The Indian Journal of Gastroenterology has documented rising rates of celiac disease and inflammatory bowel disease, with women disproportionately affected. But the research base remains thin, and many women go years without a correct diagnosis.

Autoimmune disease is a women's health crisis. It is also a gastroenterological crisis. The two are the same crisis, and we are ignoring both.

What Needs to Change

Closing the gut health gender gap requires change at every level of the research pipeline. Funding agencies must require sex-disaggregated data in gut health research. Clinical trials must enrol women in proportions that reflect the actual patient population. Basic science must include female animals and cell lines. And clinicians must be trained to recognise and treat gender differences in gut disease.

In India, where the burden of gastrointestinal disease is high and the research base is thin, these changes are urgent. Indian medical institutions must invest in gut health research that accounts for sex, gender, and the specific dietary and cultural contexts of Indian populations.

The gut health gender gap is not an academic curiosity. It is a clinical emergency. Women are being misdiagnosed, undertreated, and dismissed because the research was never designed to find them.

Closing this gap is not just a matter of fairness. It is a matter of medical accuracy. A medicine that does not understand women's bodies is not medicine. It is guesswork.